• Shanghai Junshi Biosciences posted revenue of RMB 1.7 billion for the six months ended June 30, up 45%.
• Loss for the period narrowed to RMB 36.99 million from RMB 466.41 million a year earlier.
• Profit attributable to owners turned to RMB 25.5 million, while basic earnings per share were RMB 0.02.
• R&D expenses fell 14% to RMB 643.94 million, while selling and distribution costs rose 4% to RMB 507.17 million.
• TUOYI domestic sales revenue reached RMB 1.3 billion, up 36%, and total revenue rose on higher pharmaceutical product sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Junshi Biosciences Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260924-12344484), on September 24, 2026, and is solely responsible for the information contained therein.